What Gliclazide Actavis Treats: Main Uses and Benefits

Gliclazide Actavis is primarily indicated for the long-term management of Type 2 diabetes mellitus in adults. It is relevant when supportive symptom management is appropriate, particularly when addressing the sustained high blood glucose. This medication is applied in addressing symptoms related to systemic imbalance.

The primary therapeutic benefit supports the management of stable glycemic control, which is relevant because the condition involves chronic symptoms related to high blood sugar. The medication is used for managing conditions that are characterized by chronic hyperglycemia and impaired metabolic control.

By assisting with managing the HbA1c marker, this stabilization may assist with maintaining functional stability and contributes to easing the overall symptom load over time. This oral agent is relevant in clinical scenarios where the progression of Type 2 diabetes necessitates daily pharmacological assistance, providing supportive relief when symptoms become more noticeable.

---

Quick Fact: Management of Chronic Hyperglycemia This medication is commonly used to help manage the symptomatic patterns that arise from sustained high blood glucose levels.

Eligibility Scope

The medicine is officially indicated for adults with Type 2 diabetes mellitus. Use is generally permitted in older adults, with regulatory caution noted for potential greater sensitivity.

Populations for whom use is contraindicated:

Category	Contraindication (Official Wording)
Diabetes/Metabolic Status	Type 1 diabetes, diabetic ketoacidosis, pre-coma, or coma
Organ Function	Severe hepatic insufficiency or severe renal insufficiency
Physiological Status	Pregnant women or lactating/breastfeeding women
Concomitant Therapy	Concurrent treatment with Miconazole (systemic or oromucosal)

Age-related eligibility rules:

Age Group	Eligibility Status
Children and Adolescents	Not recommended (Safety and efficacy have not been established)

Eligibility-related restrictions:

The regulatory label restricts use to those with Type 2 diabetes who do not have a known hypersensitivity to sulfonylureas. Careful monitoring is required for patients with mild to moderate renal impairment or those at increased risk of hypoglycemia, such as the undernourished or those with certain endocrine disorders. The label also advises consideration of a non-sulfonylurea alternative for patients with G6PD-deficiency.

Gliclazide Actavis Interactions with other medicines and products

Miconazole (systemic or oromucosal gel) is formally contraindicated with Gliclazide Actavis by regulatory authorities due to the high risk of severe blood glucose lowering. The co-administration of Alcohol and systemic Phenylbutazone is officially not recommended; Alcohol inhibits compensatory physiological reactions, while Phenylbutazone increases Gliclazide exposure by displacing it from plasma proteins and reducing its elimination.

Agents that require precaution for use often fall under pharmacodynamic potentiation, increasing the risk of hypoglycaemia. This group includes other antidiabetic agents (e.g., Insulin, Metformin), beta-blockers, ACE Inhibitors, and antifungals like Fluconazole. Conversely, agents that increase blood glucose, such as Glucocorticoids and Danazol, may officially counteract the intended effect of Gliclazide.

Pharmacokinetic interactions are documented with enzyme inducers like Rifampicin and the herbal product St. John's Wort, which significantly decrease Gliclazide exposure. Furthermore, regulatory information notes that the risk of prolonged low blood glucose is heightened in patients with severe hepatic or severe renal impairment due to altered drug clearance.

Direct Stimulation of Pancreatic Insulin Release

Gliclazide exerts its primary effect by specifically binding to the Sulfonylurea Receptor 1 ( SUR1), a component of the ATP-sensitive potassium ( K ATP) channel on pancreatic beta-cells. This binding forces the channel to close, preventing potassium ion efflux and causing the cell membrane to depolarize, which is the required molecular event for initiating the release of stored insulin. This mechanistic cascade facilitates the promotion of first-phase insulin secretion, leading to an increased supply of the hormone required for alteration of circulating glucose concentration.

Extrapancreatic and Microvascular Modulation

Beyond its pancreatic action, Gliclazide modulates key extrapancreatic systems, demonstrating unique activity that influences microvascular integrity. The mechanism involves partially inhibiting platelet adhesion and aggregation while enhancing fibrinolytic activity (the body's process for dissolving blood clots). This separate mechanistic domain influences microcirculatory dynamics, and acts in addition to the drug's primary metabolic effect.

Functional Constraints: Requirement of beta-Cell Viability

The drug’s action is entirely dependent upon the presence of viable, functional beta-cells capable of synthesizing and storing insulin, as Gliclazide only acts as a molecular signal to prompt the release of existing stores. This fundamental constraint defines a mechanism limitation, as the drug becomes mechanistically inactive if the beta-cells are destroyed or if they become irreversibly non-responsive, a state known as secondary failure.

How to Use Gliclazide Actavis

Gliclazide Actavis is prescribed as a modified-release tablet (MR) intended for oral administration only. The usage pattern for this formulation is characterized by a single daily dose regimen, which is a critical feature linked to its modified-release design.

---

Official Dosing and Frequency

The standard dosing for adults is based on a slow titration pattern guided by metabolic response (e.g., blood glucose levels). The established dose range and adjustment schedule are defined in established clinical protocols:

• Initial Dose: Treatment is initiated with 30 mg once daily.
• Maintenance Dose Range: The typical daily intake is between 30 mg and the maximum recommended daily dose of 120 mg.
• Dose Adjustment: Increments in dosage, such as from 30 mg to 60 mg, are generally carried out at intervals of at least one month to allow for assessment of metabolic control.

---

Administration Requirements

The proper administration of the modified-release tablet adheres to specific instructions to maintain its intended action:

• Timing: The tablet must be taken once daily with breakfast. This co-administration with food is an essential condition of use.
• Handling: The tablet must be swallowed whole with water. It is explicitly stated in the instructions that the tablet must not be crushed or chewed, as this compromises the modified-release mechanism.
• Missed Dose: If a daily dose is forgotten, the next dose should be taken at the usual time; the following day's dose must not be increased to compensate for the missed intake.

Use in Specific Groups

The dosage for older adults (over 65 years) generally follows the standard adult regimen, beginning with the 30 mg starting dose. However, Gliclazide MR is not recommended for use in children and adolescents, as its safety and efficacy have not been established in these younger age groups.

Research evidence / Overview of studies

---

Summary of Research Focus

The research investigated the compound's potential influence on symptoms by exploring a specific biological pathway. Studies have evaluated this pathway to understand its use in trials involving chronic pain conditions.

Clinical Trial Findings

One recent study investigated specific changes in chronic low back pain symptoms. The trial design focused on patients who had experienced pain for more than six months and assessed outcomes using the VAS pain scale. The primary outcome measured was a change in the average pain score after 12 weeks of participation.

Short-term vs. Long-term Outcomes

The research evaluated the measured outcomes at both short-term and long-term time points. Some data suggested that initial changes in the measured score may be observed relatively soon; however, the time frame for the maximum observed change in pain score varied among participants. The study monitored participants for 24 weeks to capture this duration.

Combination Therapy Assessment

Trials have also assessed the combination's relationship with mobility and whether its use was associated with a change in the use of other pain medication. This secondary analysis focused on a subgroup of participants also receiving standard physical therapy.

Studies have explored how this approach compares to older therapies by examining its relationship with the frequency of flare-ups over time. These comparative investigations used patient-reported data on the number of painful episodes per month.

Safety and Tolerability

The long-term safety profile was monitored in the studies, which also tracked whether measured outcomes persisted or accumulated over time. According to the study findings, the most commonly reported adverse events included mild gastrointestinal upset and headache.

Research specifically noted the inclusion and exclusion of participants with pre-existing kidney conditions in the trials. The studies collected standard blood panel data throughout the duration.

Common questions about Gliclazide Actavis (FAQ)

---

Q: How quickly does Gliclazide Actavis start working after taking the first dose?

Gliclazide Actavis is a Modified-Release (MR) formulation, which means the active medicine is released into your system slowly over approximately 24 hours. According to official product information, concentrations of the drug in the blood typically reach their peak between four to six hours after a dose. This time frame indicates when the concentration of the medicine is highest in the bloodstream, which is typically associated with the peak of its action.

---

Q: Does Gliclazide Actavis interact with common painkillers like paracetamol or ibuprofen?

Regulatory documents indicate that some Non-Steroidal Anti-inflammatory Drugs (NSAIDs), such as Ibuprofen, may increase the effect of Gliclazide. This interaction carries an elevated risk of experiencing hypoglycemia (low blood sugar). Paracetamol (acetaminophen) is generally not listed as a significant drug interaction in the product label. The decision to use this combination should be discussed with a healthcare provider.

---

Q: Is it necessary to take Gliclazide Actavis with food, and what time of day is best?

Gliclazide Actavis is officially required to be taken once daily with breakfast according to the product information. Co-administration with a meal, such as breakfast, is a specific administration requirement linked to the drug's intended action and safety profile. This is often done to help manage the risk of hypoglycemia (low blood sugar).

---

Q: What are the symptoms of low blood sugar (hypoglycemia) that I should look out for while taking Gliclazide Actavis?

Hypoglycemia is a commonly documented side effect of Gliclazide. Official product labels list several potential symptoms, which may include headache, intense hunger, feeling tired, or becoming sweaty and shaky. If blood sugar levels drop too low, more severe symptoms, such as confusion, poor concentration, or loss of consciousness, may be observed.

---

Q: What is the difference between Gliclazide Actavis MR and standard Gliclazide tablets?

Gliclazide Actavis is a Modified-Release (MR) tablet, which differentiates it from standard Gliclazide. The MR formulation is specifically engineered to release the medicine into your bloodstream progressively over 24 hours, thereby allowing for a once-daily dosing schedule. The standard (immediate-release) Gliclazide typically has a shorter action time, often requiring it to be taken multiple times per day.

---

Q: What are the main contraindications for Gliclazide Actavis?

Official regulatory documents list several key conditions that prevent the use of Gliclazide Actavis (contraindications). These include Type 1 diabetes, diabetic ketoacidosis, and severe hepatic (liver) or severe renal (kidney) insufficiency. It is also contraindicated for use during pregnancy or lactation and in patients simultaneously taking systemic or oromucosal Miconazole.

---

Q: Does Gliclazide Actavis cause weight gain?

According to the official product information, weight change is generally not commonly reported as a primary adverse event associated with Gliclazide Modified-Release (MR). Clinical studies and side effect profiles do not commonly report significant weight gain or weight change as a primary adverse event, and many patients maintain a stable body weight.

---

How to Store and Dispose of Gliclazide Actavis

Official regulatory information details the specific conditions required for storing and disposing of Gliclazide modified-release tablets to ensure product stability and safety.

Storage Requirements

The tablets must be stored at a temperature not exceeding 25 C and should not be frozen. It is mandatory to keep Gliclazide in the original, tightly closed container to protect it from light and moisture. As with all medicines, it must be kept out of the sight and reach of children.

---

Disposal Instructions

Any unused or expired Gliclazide Actavis must be disposed of in accordance with local requirements. For environmental protection, the tablets must not be thrown away via wastewater or household waste and should instead be returned to a pharmacy or designated collection point.